Jay Lalezari 14:52: Absolutely. The first order of

Jay Lalezari 14:52: Absolutely. The first order of business is for us to prospectively confirm what we've seen retrospectively. When we do that, it's a game-changer for CytoDyn. I think it's a game-changer for patients with CCR5-positive solid tumors. And at that point, we've spoken to quite a number of the pharmaceutical entities that have checkpoint assets, and they're really just waiting to see us confirm this signal prospectively before diving in, because it gives them an opportunity, not only will patients benefit, but it'll give the companies an opportunity to vastly expand their markets.

Which companies have "checkpoint assets" in addition to Merck? It seems obvious that discussions have been held with them and they are the entities awaiting confirmation.